Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.30 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 1,154 | 0.73 |
| pathways Reactome | 6 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 1290
Sealed predictions
- ANXA2 in dopamine neurons, braak-0.45 (p 0.230) → +0.44 (p 0.235)receipt 1296
Swarm cases
receipt 1296: ANXA2 in dopamine neurons, braak
- power
- full sample -0.00 (p 0.990, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.05 (p 0.847, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.13 (p 0.615, n 18). could be the mix.
- skeptic
- leave-one-out range -0.12 to +0.14, sign flips 9; without severely affected donors -0.00 (p 0.990, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ANXA2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts